Sign In
Buy IDRSF
$5.75
+0 (+0%)
At Close: Jun 02, 2026
Idorsia announces the appointment of Srishti Gupta, MD as CEO to ensure the long-term success of Idorsia
01:00am, Tuesday, 10'th Jun 2025
Ad hoc announcement pursuant to Art. 53 LR André C.
Idorsia publishes invitations to bondholder meetings
01:00am, Friday, 06'th Jun 2025
Ad hoc announcement pursuant to Art. 53 LR Bondholder meetings will take place on Wednesday, June 25, 2025, to vote on proposals to amend the terms of the two outstanding convertible bonds CB 2025 and
Shareholders vote in favor of all proposals by the Board at Idorsia's Annual General Meeting 2025
05:23am, Wednesday, 28'th May 2025
Allschwil, Switzerland – May 28, 2025 At today's Annual General Meeting (AGM) of Idorsia Ltd (SIX: IDIA) held in Basel, Switzerland, shareholders voted convincingly in favor of all proposals by the
New funds secured – allowing the commercial ramp-up of QUVIVIQ to accelerate Idorsia's path to profitability
01:00am, Wednesday, 21'st May 2025
Ad hoc announcement pursuant to Art. 53 LR CHF 150 million new money facility from bondholders now implemented and providing cash runway to mid-2026 Holistic convertible debt restructuring progressing
Idorsia issues invitation to the 2025 Annual General Meeting of Shareholders
01:00am, Friday, 02'nd May 2025
Allschwil, Switzerland – May 2, 2025 Idorsia Ltd (SIX: IDIA) today issued the invitation to the upcoming Annual General Meeting (AGM) of Shareholders on behalf of the Board of Directors. The meeting
Idorsia publishes its Annual Report 2024
02:00am, Thursday, 27'th Mar 2025
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – March 27, 2025 Idorsia Ltd (SIX: IDIA) today announced the publication of the Annual Report 2024 – consisting of the Business Re
Idorsia announces the publication of positive data with daridorexant in patients with chronic insomnia and nocturia
02:00am, Friday, 14'th Mar 2025
Allschwil, Switzerland – March 14, 2025 Idorsia Ltd (SIX: IDIA) today announced the publication of “A randomized cross-over trial of daridorexant for the treatment of chronic insomnia and nocturia
Idorsia Ltd (IDRSF) Q4 2024 Earnings Call Transcript
10:59am, Tuesday, 04'th Mar 2025
Idorsia Ltd (OTC:IDRSF) Q4 2024 Earnings Conference Call March 4, 2025 8:00 AM ET Company Participants Andrew Jones - Senior Vice President, Head of Corporate Communications & Investor Relations Andre
Idorsia announces financial results for 2024
01:00am, Tuesday, 04'th Mar 2025
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – March 4, 2025 Idorsia Ltd (SIX: IDIA) today announced its financial results for 2024.
Invitation to Idorsia's Full Year 2024 Financial Reporting webcast and conference call
11:51am, Thursday, 27'th Feb 2025
Idorsia will publish its Full Year 2024 Financial Reporting on Tuesday March 4, 2025, at 07:00 CET. An investor webcast and conference call will be held to discuss the results on the same day.
Ad hoc announcement pursuant to Art. 53 LR More than the required two-thirds majority of bondholders reach agreement on the main terms for the restructuring of Idorsia's outstanding convertible bond d
Idorsia and Viatris update their collaboration for selatogrel and cenerimod
12:55am, Wednesday, 26'th Feb 2025
Ad hoc announcement pursuant to Art. 53 LR Idorsia's contribution to the development costs reduced by USD 100 million Viatris potential regulatory and sales milestones payments to Idorsia reduced by U
Idorsia is released from exclusivity constraint regarding the global rights to aprocitentan – now pivoting to alternative parties
12:50am, Wednesday, 26'th Feb 2025
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – February 26, 2025 Idorsia Ltd (SIX: IDIA) today announced that the exclusivity agreement signed in November 2024 with an undisclos
Idorsia publishes the resolutions for the upcoming bondholder meeting
05:00pm, Wednesday, 12'th Feb 2025
Ad hoc announcement pursuant to Art. 53 LR The updated invitation to the bondholder meeting – scheduled for February 25, 2025 – sets out the terms of the resolutions to be voted upon Unaudited Fin
Idorsia presents at J.P. Morgan Healthcare Conference 2025 – fighting to create value for all stakeholders
05:45pm, Wednesday, 15'th Jan 2025
Ad hoc announcement pursuant to Art. 53 LR Presentation to take place on January 15, 2025, at 15:00 PST / 00:00 CET and will be available for replay on demand Allschwil, Switzerland – January 15, 20
